Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

Inclusion Criteria

• •Give their signed written informed consent to participate.
• •Are at least 40 years of age and no older than 80 at Visit 1.
• •A female of non-child bearing potential or child bearing potential, has a negative serum pregnancy test, and agrees to approved contraceptive methods.
• •COPD Diagnosis: Subjects with an established clinical history of COPD as defined by the American Thoracic Society(ATS)/European Respiratory Society (ERS).
• •Current or former smokers with a history of at least 10 pack-years of cigarette smoking.
• •FEV1/FVC ratio of \<0.70.
• •Post-bronchodilator FEV1 must be ≥ 30% and \<80% predicted normal value calculated using the Third National Health and Nutrition Examination Survey (NHANES III) reference equations, and must also be greater than or equal to 750 mL.
• •Subject is willing and, in the opinion of the Investigator, able to adjust current COPD therapy as required by the protocol.